Trademark Search in Canada

OMJJARA

View On IC.GC.CA

REGISTERED

on 9 Apr 2025

Last Applicant/ Owned by

GlaxoSmithKline LLC

Corporation Service Company251 Little Falls DriveWilmington, DE 19808

Serial Number

2191873 filed on 15^th Jun 2022

Registration Number

TMA1305466 registered on 9^th Apr 2025

Registration expiry Date

9^th Apr 2035

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

K1P1J9

OMJJARA

Trademark usage description

pharmaceutical preparations and drugs for the treatment of cancer, namely, myelofibrosis (mf); pharmaceutical preparations and drugs for the treatment Read More

Classification Information

Class [005]
Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and disorders; Biological preparations made from living tissues for the treatment of cancer; chemical preparations for medical purposes for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Diagnostic reagents for medical purposes; Medical diagnostic reagents, assays, and test kits for testing of body fluids; Cells protein molecules and molecular compounds, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals to treat cancer; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use

Classification kind code

Class [042]
Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; Scientific research and development in the field of cancer treatment and diagnosis, medical research services; Scientific research laboratories for conducting research in the field of cancer, cancer prevention and cancer diagnosis; Medical research laboratory services; conducting clinical trials for others; conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes

Classification kind code

Class [044]
Medical diagnostic services, medical examination services, medical analysis services for cancer diagnosis and prognosis, medical care and analysis services relating to patient treatment, providing medical information in the field of cancer treatment; medical testing services; DNA screening and analysis services for medical purposes

Classification kind code

Mark Details

Serial Number

2191873

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 23^rd Sept 2024	Search Recorded
Submitted for opposition 80 on 20^th Mar 2023	Change of Title Registered
Submitted for opposition 135 on 16^th Feb 2023	Amendment to Application
Submitted for opposition 135 on 8^th Feb 2023	Amendment to Application
Submitted for opposition 83 on 1^st Feb 2023	Assignment Correspondence Created
Submitted for opposition 48 on 12^th Oct 2022	Agent Changed
Submitted for opposition 287 on 21^st Jul 2022	Pre-Assessment Letter Sent
Submitted for opposition 30 on 15^th Jun 2022	Filed
Submitted for opposition 1 on 15^th Jun 2022	Created
Submitted for opposition 31 on 15^th Jun 2022	Formalized